Key result
Transcriptome analysis of 160 soft tissue sarcomas with complex genomics identified five distinct tumor groups and highlighted recurrent alterations in RB1, PTEN, and the WNT canonical pathway.
Observational (n=160)
Comprehensive genomic analysis of complex soft tissue sarcomas reveals distinct molecular subgroups and highlights RB1, PTEN, and WNT pathways as potential therapeutic targets.
Should not yet change sarcoma management; leaves open validation of RB1/PTEN/WNT-targeted trials in molecular subgroups.
Adult soft tissue sarcomas (STS) are rare tumours of mesenchymal lineage. Based on cytogenetic and comparative genomic hybridization (CGH) data, they can be divided into 'STS with simple genomics', displaying a characteristic genetic alteration, and 'STS with complex genomics' (SCG), where multiple genomic alterations occur. This latter group is mostly composed of leiomyosarcomas (LMS) and pleiomorphic undifferentiated tumours previously labelled as 'malignant fibrous histiocytomas' (MFH), corresponding in fact to myxofibrosarcomas (MFS), pleiomorphic liposarcomas/rhabdomyosarcomas (P-LPS, P-RMS), and undifferentiated pleiomorphic sarcomas (UPS). Their pathobiology is still not well understood, leading to challenges in diagnosis and therapeutic management. We report here a comprehensive study encompassing array-CGH and transcriptome analysis data of a large series of 160 SCG. Non-supervised clustering of transcriptome data led to the identification of five groups of tumours, one of them (group A) corresponding to well-differentiated LMS and the other four (B-E) to 'MFH' and poorly differentiated LMS. Welch analysis of transcriptome data in these groups allowed us to retrieve several genes of potential interest. Among them, RB1 alteration is a constant thread in SCG, often associated with RBL2 loss. PTEN tumour suppressor deletion would also stand out as a major recurrent event, especially in groups A, C, and D. The WNT canonical pathway could be potentially involved, as demonstrated by up-regulation of one of its inhibitors, DKK1, in groups D and E, whereas DKK1 is significantly down-regulated in groups A, B, and C. These data suggest a very complex interplay between pathways downstream of PTEN and the WNT canonical pathway, providing new hints about SCG pathobiology and their potential therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Gibault et al. (2010) conducted an observational in Soft tissue sarcomas with complex genomics (n=160). Genomic and transcriptome profiling was evaluated on Identification of transcriptome groups and recurrent genetic alterations. Transcriptome analysis of 160 soft tissue sarcomas with complex genomics identified five distinct tumor groups and highlighted recurrent alterations in RB1, PTEN, and the WNT canonical pathway.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: